A prospective trial investigating the role of Serum 25-Hydroxyvitamin D in diagnosis and prognosis of bladder cancer.
<h4>Purpose</h4>Higher levels of serum 25-hydroxyvitamin D 25(OHD) are associated with better prognosis in breast and colorectal cancer. However, the evidence is still inconclusive for bladder cancer (BC). Herein, we investigated the diagnosis and prognosis roles of serum levels of 25(OH...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0266371 |
| _version_ | 1828184807061848064 |
|---|---|
| author | Ahmed Abdelgawad Abdelwahab Hashem Ahmed Mosbah Laila A Eissa |
| author_facet | Ahmed Abdelgawad Abdelwahab Hashem Ahmed Mosbah Laila A Eissa |
| author_sort | Ahmed Abdelgawad |
| collection | DOAJ |
| description | <h4>Purpose</h4>Higher levels of serum 25-hydroxyvitamin D 25(OHD) are associated with better prognosis in breast and colorectal cancer. However, the evidence is still inconclusive for bladder cancer (BC). Herein, we investigated the diagnosis and prognosis roles of serum levels of 25(OHD) in suspected BC patients presented by hematuria.<h4>Methods</h4>This prospective cohort study involved suspected patients of BC presented with hematuria. Patients were evaluated by CT urogram, office cystoscopy and urine cytology with subsequent inpatient biopsy for positive findings. Baseline blood samples were collected for measurement of 25(OHD) by electrochemiluminescence binding assay at the time of diagnosis. Patients with non-muscle-invasive BC (NMIBC) underwent transurethral resection of bladder tumor (TURBT) and adjuvant intravesical chemotherapy or BCG instillation. Patients were followed up for their recurrence status during 10 to 24 months. Recurrence was defined as the first time of NMIBC pathological relapse during the follow up period.<h4>Results</h4>A total of 115 patients were included in the final analysis. Patients had proven pathological BC (64 with NMIBC, and 20 with muscle invasive) and 31 patients were considered as control group. Controls were those patients with BC-free workup (including cytology, cystoscopy, and upper tract imaging). BC group showed a lower level of 25(OHD) than control group 16.47±5.88 versus 28.99±3.19 ng/mL (p<0.001). In addition, muscle invasive group also showed a lower level than NMIBC group 13.17±4.5 versus 17.49±5.04 ng/mL (P = 0.003). During the follow-up period of, tumor recurrence occurred in 16 (25%) of NMIBC patients. The baseline 25(OHD) were decreased in patients who experienced early recurrence; without being statistically significant (15.99 ± 5.17 vs. 18.38 ± 5.14 ng/mL; p = 0.08). 25(OHD) deficiency/insufficiency occurred in 5 (16.1%) and 64 (76.2%) in control and BC patients, respectively, (odds-ratios (OR): 2.13; 95% confidence intervals (CI), 1.52-2.99; P < 0.0001).<h4>Conclusion</h4>Serum 25(OHD) is significantly decreased in BC patients especially those with tumor muscle invasive group. However, the baseline serum 25(OHD) does not predict the recurrence in the NMIBC patients. |
| first_indexed | 2024-04-12T06:55:59Z |
| format | Article |
| id | doaj.art-5c578e9fffdc467ab098f49ff3982d14 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-12T06:55:59Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-5c578e9fffdc467ab098f49ff3982d142022-12-22T03:43:10ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01176e026637110.1371/journal.pone.0266371A prospective trial investigating the role of Serum 25-Hydroxyvitamin D in diagnosis and prognosis of bladder cancer.Ahmed AbdelgawadAbdelwahab HashemAhmed MosbahLaila A Eissa<h4>Purpose</h4>Higher levels of serum 25-hydroxyvitamin D 25(OHD) are associated with better prognosis in breast and colorectal cancer. However, the evidence is still inconclusive for bladder cancer (BC). Herein, we investigated the diagnosis and prognosis roles of serum levels of 25(OHD) in suspected BC patients presented by hematuria.<h4>Methods</h4>This prospective cohort study involved suspected patients of BC presented with hematuria. Patients were evaluated by CT urogram, office cystoscopy and urine cytology with subsequent inpatient biopsy for positive findings. Baseline blood samples were collected for measurement of 25(OHD) by electrochemiluminescence binding assay at the time of diagnosis. Patients with non-muscle-invasive BC (NMIBC) underwent transurethral resection of bladder tumor (TURBT) and adjuvant intravesical chemotherapy or BCG instillation. Patients were followed up for their recurrence status during 10 to 24 months. Recurrence was defined as the first time of NMIBC pathological relapse during the follow up period.<h4>Results</h4>A total of 115 patients were included in the final analysis. Patients had proven pathological BC (64 with NMIBC, and 20 with muscle invasive) and 31 patients were considered as control group. Controls were those patients with BC-free workup (including cytology, cystoscopy, and upper tract imaging). BC group showed a lower level of 25(OHD) than control group 16.47±5.88 versus 28.99±3.19 ng/mL (p<0.001). In addition, muscle invasive group also showed a lower level than NMIBC group 13.17±4.5 versus 17.49±5.04 ng/mL (P = 0.003). During the follow-up period of, tumor recurrence occurred in 16 (25%) of NMIBC patients. The baseline 25(OHD) were decreased in patients who experienced early recurrence; without being statistically significant (15.99 ± 5.17 vs. 18.38 ± 5.14 ng/mL; p = 0.08). 25(OHD) deficiency/insufficiency occurred in 5 (16.1%) and 64 (76.2%) in control and BC patients, respectively, (odds-ratios (OR): 2.13; 95% confidence intervals (CI), 1.52-2.99; P < 0.0001).<h4>Conclusion</h4>Serum 25(OHD) is significantly decreased in BC patients especially those with tumor muscle invasive group. However, the baseline serum 25(OHD) does not predict the recurrence in the NMIBC patients.https://doi.org/10.1371/journal.pone.0266371 |
| spellingShingle | Ahmed Abdelgawad Abdelwahab Hashem Ahmed Mosbah Laila A Eissa A prospective trial investigating the role of Serum 25-Hydroxyvitamin D in diagnosis and prognosis of bladder cancer. PLoS ONE |
| title | A prospective trial investigating the role of Serum 25-Hydroxyvitamin D in diagnosis and prognosis of bladder cancer. |
| title_full | A prospective trial investigating the role of Serum 25-Hydroxyvitamin D in diagnosis and prognosis of bladder cancer. |
| title_fullStr | A prospective trial investigating the role of Serum 25-Hydroxyvitamin D in diagnosis and prognosis of bladder cancer. |
| title_full_unstemmed | A prospective trial investigating the role of Serum 25-Hydroxyvitamin D in diagnosis and prognosis of bladder cancer. |
| title_short | A prospective trial investigating the role of Serum 25-Hydroxyvitamin D in diagnosis and prognosis of bladder cancer. |
| title_sort | prospective trial investigating the role of serum 25 hydroxyvitamin d in diagnosis and prognosis of bladder cancer |
| url | https://doi.org/10.1371/journal.pone.0266371 |
| work_keys_str_mv | AT ahmedabdelgawad aprospectivetrialinvestigatingtheroleofserum25hydroxyvitamindindiagnosisandprognosisofbladdercancer AT abdelwahabhashem aprospectivetrialinvestigatingtheroleofserum25hydroxyvitamindindiagnosisandprognosisofbladdercancer AT ahmedmosbah aprospectivetrialinvestigatingtheroleofserum25hydroxyvitamindindiagnosisandprognosisofbladdercancer AT lailaaeissa aprospectivetrialinvestigatingtheroleofserum25hydroxyvitamindindiagnosisandprognosisofbladdercancer AT ahmedabdelgawad prospectivetrialinvestigatingtheroleofserum25hydroxyvitamindindiagnosisandprognosisofbladdercancer AT abdelwahabhashem prospectivetrialinvestigatingtheroleofserum25hydroxyvitamindindiagnosisandprognosisofbladdercancer AT ahmedmosbah prospectivetrialinvestigatingtheroleofserum25hydroxyvitamindindiagnosisandprognosisofbladdercancer AT lailaaeissa prospectivetrialinvestigatingtheroleofserum25hydroxyvitamindindiagnosisandprognosisofbladdercancer |